Trial of Mesalamine for the Treatment of Active Microscopic Colitis
|ClinicalTrials.gov Identifier: NCT00952952|
Recruitment Status : Completed
First Posted : August 6, 2009
Last Update Posted : May 24, 2011
|Condition or disease||Intervention/treatment||Phase|
|Microscopic Colitis Diarrhea||Drug: Mesalamine||Phase 2 Phase 3|
We propose a prospective, randomized trial of mesalamine at 1.2g and 4.8g doses for the treatment of microscopic colitis. Our hypothesis is mesalamine is safe and effective for the treatment of diarrhea in microscopic colitis and that the 4.8g dose is more effective than the 1.2g dose.
We will recruit 70 subjects. The subjects will be randomized into to two groups, 4.8g dose, and 1.2g dose groups. Subjects will receive medication for 8 weeks, followed by sigmoidoscopy with biopsies. The subjects will be monitored weekly. A pathologist will review pre and post treatment biopsies. Responders will be followed for 4 weeks post medication.
Subjects must be 18 years old and older, have diarrhea and microscopic colitis. Subjects will be excluded if they have unsuccessful treatment or side effects to 5-ASA drugs, oral corticosteroids, or salicylate. and antibiotics, mesalamine, bismuth or steroid use in the last two weeks. Subjects may not be on anticholinergics, cholestyramine, digoxin. Pregnant or nursing females are excluded. They can't have other untreated diarrheal conditions.
A two-sample z-score test for proportions will be used to test whether relief rates are different between groups.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||70 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Dose Ranging Trial of Mesalmine for the Treatment of Active Microscopic Colitis.|
|Study Start Date :||February 2007|
|Primary Completion Date :||November 2007|
|Study Completion Date :||November 2007|
- To determine the efficacy of mesalamine at 1.2g and 4.8g doses in microscopic colitis for providing relief of diarrhea
- To compare the safety and tolerability of mesalamine at 1.2g and 4.8g doses in patients with microscopic colitis.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00952952
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|